Toronto, ON (June 17, 2021) – J. E. Davies, President and CEO of Tissue Regeneration Therapeutics (TRT), announced today the launch of a new exclusive ecommerce website for TRT’s newly branded cosmetic products TRT CELLULAR.
One of TRT’s distinctive platform technologies, TRT CELLULAR is dedicated to cosmetic products containing a proprietary cellular derivative produced from TRT’s core human umbilical cord perivascular cells, which has potent anti-inflammatory properties, and is the result of years of basic laboratory research. When added to powerful, scent-free, moisturizing base creams the resultant products have almost magical effects on the appearance and feel of the skin. Four products are currently available: a rejuvenating moisturizer for the skin; a face cream that improves the appearance by lightening and tightening the skin while reducing the appearance of wrinkles; hand cream that moisturizes without leaving any oily or greasy after-feel and an eye cream enriched with vitamins and an increased concentration of the cell derivative to hydrate and tone, diminish puffiness, and minimize the appearance of dark circles, fine lines and crow’s feet.
The cosmetics market represents an important new opportunity for TRT explained Davies, who continued to say “Extensive beta-testing of our products has shown significant efficacy with rave reviews from early users. We are particularly proud of being able to help front-line medical personnel who spend many hours each day in protective face masks and shields leaving their skin dehydrated and compromised. They report that within minutes of applying our face cream at the end of their shifts, their appearance is restored to normal and the skin has a spa-like rejuvenated feeling”.
Given the research findings focused on the cell derivative, TRT and TRT CELLULAR expect to accelerate the development of their products in the cosmeceutical market where the medicinal benefits of the products can be more directly addressed.
About Tissue Regeneration Therapeutics (TRT)
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technologies. TRT is the first company in the world to have issued and allowed international patents for the extraction of these unique cells from umbilical cord tissue. TRT provides license opportunities to collaborating partner companies in the family banking, regenerative medicine and defense sectors. Additional information is available at www.verypowerfulbiology.com.
About TRT CELLULAR
TRT CELLULAR is a division of TRT focused on cosmetic products containing a micronized cell derivative produced from human umbilical cord perivascular cells. TRT CELLULAR products are available through the TRT CELLULAR website and partnering clinics and organizations both in Canada and the USA. Additional information is available at www.TRTCellular.com.